This clinical trial is focused on studying a condition known as gastroparesis, which is a disorder that affects the normal movement of the stomach muscles, leading to delayed stomach emptying. The study specifically looks at two types of this condition: idiopathic gastroparesis, where the cause is unknown, and diabetic gastroparesis, which occurs in people with diabetes. The treatment being tested is a medication called Naronapride, which is taken as a film-coated tablet. The purpose of the study is to evaluate the effectiveness, safety, and tolerability of Naronapride in treating symptoms of gastroparesis over a 12-week period.

Participants in the study will be randomly assigned to receive either the Naronapride tablets or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The trial aims to find the optimal dose of Naronapride that provides the best balance of effectiveness and safety for patients with gastroparesis.

Throughout the study, participants will be monitored for changes in their symptoms, such as nausea, early satiety (feeling full quickly), postprandial fullness (feeling full after meals), upper abdominal pain, vomiting episodes, and bloating. The goal is to see if Naronapride can improve these symptoms compared to the placebo. The study will last for 12 weeks, during which participants will have regular check-ups to assess their progress and any side effects they may experience. This research is important for finding better ways to manage gastroparesis and improve the quality of life for those affected by this condition.